{"id":5450,"date":"2026-01-08T22:29:00","date_gmt":"2026-01-08T19:29:00","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=5450"},"modified":"2026-01-09T09:46:48","modified_gmt":"2026-01-09T06:46:48","slug":"entrada-therapeutics-announced-company-will-report-data-from-its-exon-skipping-studies-in-2026","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/entrada-therapeutics-announced-company-will-report-data-from-its-exon-skipping-studies-in-2026\/","title":{"rendered":"Entrada Therapeutics, Ekzon Atlama \u00c7al\u0131\u015fmalar\u0131ndan Elde Edilen Verileri 2026 Y\u0131l\u0131nda A\u00e7\u0131klayaca\u011f\u0131n\u0131 Duyurdu"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Entrada Therapeutics&#039;nin duyurusuna g\u00f6re, &quot;2026, Duchenne kas distrofisi i\u00e7in veri a\u00e7\u0131s\u0131ndan zengin bir y\u0131l olacak; ELEVATE-44-201&#039;nin ilk kohortundan elde edilen verilerin 2026&#039;n\u0131n ikinci \u00e7eyre\u011finde, ELEVATE-45-201&#039;den elde edilen verilerin ise 2026&#039;n\u0131n ortalar\u0131nda yay\u0131nlanmas\u0131 bekleniyor.&quot;\u2019<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ELEVATE-44-201:<\/strong> \u015eirket, ekzon 44 atlamas\u0131na uygun olan ayakta tedavi g\u00f6ren DMD hastalar\u0131nda ENTR-601-44'nin k\u00fcresel Faz 1\/2 \u00e7oklu artan doz (MAD) klinik \u00e7al\u0131\u015fmas\u0131n\u0131n 1. Kohortunun dozlamas\u0131n\u0131 tamamlad\u0131 ve \u00e7al\u0131\u015fman\u0131n a\u00e7\u0131k etiketli, Faz 2 b\u00f6l\u00fcm\u00fcne ge\u00e7ti. \u015eirket, 1. Kohorttan (6 mg\/kg) elde edilen verileri 2026 y\u0131l\u0131n\u0131n ikinci \u00e7eyre\u011finde, 2. Kohorttan (12 mg\/kg'a kadar) elde edilen verileri y\u0131l sonuna kadar ve 3. Kohorttan (18 mg\/kg'a kadar) elde edilen verileri daha sonra raporlamay\u0131 planl\u0131yor. Aral\u0131k 2025'te ABD G\u0131da ve \u0130la\u00e7 \u0130daresi (FDA), ENTR-601-44'ye Nadir Pediatrik Hastal\u0131k Tan\u0131m\u0131 verdi. <strong>Daha fazla bilgi edin:<\/strong> <a href=\"https:\/\/dmdwarrior.com\/tr\/mutations-and-deletions-amenable-to-exon-44-skipping-therapies-dmd\/\" target=\"_blank\" rel=\"noreferrer noopener\">Ekzon 44 Atlama Terapilerine Uygun Delesyonlar<\/a><\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ELEVATE-44-102:<\/strong> \u015eirket, 2026 y\u0131l\u0131n\u0131n ilk yar\u0131s\u0131nda ABD&#039;de DMD ile ya\u015fayan ayakta ve ayakta duramayan yeti\u015fkinlerde ENTR-601-44&#039;nin Faz 1b MAD klinik \u00e7al\u0131\u015fmas\u0131n\u0131 ba\u015flatmay\u0131 beklemektedir.<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ELEVATE-45-201:<\/strong> \u015eirket, ekzon 45 atlamas\u0131na uygun olan ayakta tedavi g\u00f6ren DMD hastalar\u0131nda ENTR-601-45'nin klinik \u00e7al\u0131\u015fmas\u0131n\u0131n k\u00fcresel Faz 1\/2 MAD b\u00f6l\u00fcm\u00fcnde hasta dozlamas\u0131na ba\u015flad\u0131. \u015eirket, 1. Kohorttan (5 mg\/kg) elde edilen verileri 2026 ortalar\u0131nda, 2. ve 3. Kohortlardan (s\u0131ras\u0131yla 10 mg\/kg ve 15 mg\/kg'a kadar) elde edilen verileri ise daha sonra a\u00e7\u0131klamay\u0131 planl\u0131yor. <strong>Daha fazla bilgi edin:<\/strong> <a href=\"https:\/\/dmdwarrior.com\/tr\/mutations-amenable-to-exon-45-skipping\/\" target=\"_blank\" rel=\"noreferrer noopener\">Hangi Delesyonlar Ekzon 45 Atlamaya Uygundur?<\/a><\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ELEVATE-50-201:<\/strong> \u015eirket, \u0130ngiltere \u0130la\u00e7 ve Sa\u011fl\u0131k \u00dcr\u00fcnleri D\u00fczenleme Kurumu (MHRA) ve Ara\u015ft\u0131rma Etik Kurulu'ndan, ekzon 50 atlamas\u0131na uygun, ayakta tedavi g\u00f6ren DMD hastalar\u0131nda ENTR-601-50'nin Faz 1\/2 MAD klinik \u00e7al\u0131\u015fmas\u0131n\u0131 ba\u015flatmak i\u00e7in d\u00fczenleyici onay alm\u0131\u015ft\u0131r. \u015eirket, ENTR-601-50 i\u00e7in AB'de d\u00fczenleyici ba\u015fvurular\u0131 2026 y\u0131l\u0131n\u0131n ikinci yar\u0131s\u0131nda yapmay\u0131 ve \u00e7al\u0131\u015fmay\u0131 2026 y\u0131l\u0131n\u0131n sonuna kadar ba\u015flatmay\u0131 beklemektedir. <strong>Daha fazla bilgi edin:<\/strong> <a href=\"https:\/\/dmdwarrior.com\/tr\/mutations-amenable-to-exon-50-skipping\/\">Ekzon 50 Atlama Terapilerine Uygun Delesyonlar<\/a><\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ENTR-601-51:<\/strong> \u015eirket, ENTR-601-51 i\u00e7in k\u00fcresel d\u00fczenleyici ba\u015fvurular\u0131n\u0131 2026 y\u0131l\u0131nda yapmay\u0131 planl\u0131yor. Daha fazla bilgi edinin: <a href=\"https:\/\/dmdwarrior.com\/tr\/mutations-and-deletions-amenable-to-exon-51-skipping-therapies-dmd\/\" target=\"_blank\" rel=\"noreferrer noopener\">Ekzon 51 Atlamaya Uyan Delesyonlar<\/a><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Devam\u0131n\u0131 oku<\/strong>:&nbsp;<a href=\"https:\/\/dmdwarrior.com\/tr\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Duchenne \u0130\u00e7in Klinik Ara\u015ft\u0131rmalar (T\u00fcm Ara\u015ft\u0131rmalar\u0131n Listesi)<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Entrada Therapeutics&#039;nin duyurusuna g\u00f6re, \u20192026, Duchenne kas distrofisi i\u00e7in veri a\u00e7\u0131s\u0131ndan zengin bir y\u0131l olacak; ELEVATE-44-201&#039;nin ilk kohortundan elde edilen verilerin 2026&#039;n\u0131n ikinci \u00e7eyre\u011finde, ELEVATE-45-201&#039;den elde edilen verilerin ise 2026&#039;n\u0131n ortalar\u0131nda yay\u0131nlanmas\u0131 bekleniyor.\u201c Daha Fazla Bilgi: Duchenne i\u00e7in Klinik \u00c7al\u0131\u015fmalar (T\u00fcm Ara\u015ft\u0131rmalar\u0131n Listesi)<\/p>","protected":false},"author":1,"featured_media":5452,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[242,233,234,246,319,475,421],"class_list":["post-5450","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-clinical-trials","tag-entrada","tag-entrada-therapeutics","tag-exon-44-skipping-therapies","tag-exon-45-skipping-therapy","tag-exon-50-skipping-therapy","tag-exon-51-skipping-therapy"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/5450","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=5450"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/5450\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/5452"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=5450"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=5450"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=5450"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}